How Accurate Is NIPT Testing for Chromosomal Conditions?

NIPT is remarkably accurate for the most common chromosomal condition it screens for, Down syndrome, catching more than 99% of cases with a specificity also above 99%. But that headline number masks real variation. Accuracy drops for rarer conditions like Edwards and Patau syndromes, falls further for sex chromosome differences, and becomes genuinely unreliable for microdeletions and rare trisomies. The gap between “screening” and “diagnosis” matters here more than in almost any other area of medicine, because what the test is actually measuring is not the baby’s DNA at all.

What NIPT Actually Measures

The term “cell-free fetal DNA” is a bit of a misnomer. The DNA fragments floating in your blood during pregnancy come from the placenta, not directly from the fetus. As the placenta grows, its outer layer of cells constantly turns over, shedding tiny fragments of DNA into your bloodstream.¹ These fragments tend to be short and are cleared rapidly after delivery, which is why the test works during pregnancy and not after.²

This distinction between placental and fetal DNA is not just a technicality. The placenta and the fetus usually share the same chromosomes, but not always. When they differ, you get a false result. That biological reality is the single biggest reason NIPT can never function as a definitive diagnosis on its own.

Down Syndrome Detection

For trisomy 21, the evidence is strong and consistent. A systematic review and meta-analysis pooling data from multiple studies found a sensitivity of 99.3% and a specificity of 99.9%.³ A large clinical study covering nearly 147,000 pregnancies reported similar numbers: sensitivity of 99.17% and specificity of 99.95%.⁴ That same study found no meaningful difference in performance between women classified as high-risk and those classified as low-risk, which was a meaningful finding because earlier guidance had restricted NIPT to high-risk pregnancies.

Those numbers sound almost perfect, but sensitivity and specificity alone do not tell you how likely a positive result is to be correct. That question depends on the positive predictive value, which factors in how common the condition is in the population being tested. For trisomy 21, the PPV remains relatively high because Down syndrome is the most common autosomal trisomy. One study of nearly 69,000 pregnancies found a PPV of about 65% for trisomy 21.⁵ In other words, roughly a third of women who screen positive for Down syndrome on NIPT will learn after confirmatory testing that the result was a false alarm. That is dramatically better than older screening methods, but it is also not something that should be described as “99% accurate” to patients without context.

Edwards and Patau Syndromes

For trisomy 18 (Edwards syndrome) and trisomy 13 (Patau syndrome), sensitivity is slightly lower than for Down syndrome. The pooled figures from meta-analysis are 97.4% for both conditions, with specificity remaining above 99.9%.³ The real difference shows up in the PPV. Because trisomies 18 and 13 are much rarer than trisomy 21, the math means a higher proportion of positive screens are false positives. In the 69,000-pregnancy study, the PPV was about 36% for trisomy 18 and about 18% for trisomy 13.⁵

That means if you receive a positive NIPT result for Patau syndrome, there is roughly a four-in-five chance it is a false positive. This does not mean the test is poorly designed. It reflects a mathematical reality: when a condition is very rare, even a test with extremely high specificity will produce more false alarms than true detections in an unselected population. This is one reason clinicians and professional societies consistently emphasize that NIPT is a screening tool, not a diagnostic one.

Sex Chromosome Differences

NIPT accuracy drops more substantially when screening for sex chromosome aneuploidies like Turner syndrome (45,X), Klinefelter syndrome (47,XXY), Triple X (47,XXX), and 47,XYY. As a group, sex chromosome aneuploidies actually occur more frequently than any single autosomal trisomy, affecting roughly 1 in 400 pregnancies, but the biology makes them harder to screen for. Mosaicism plays a bigger role, the phenotypic range is wider, and the positive predictive value is substantially lower than for trisomy 21.⁶

A systematic review and meta-analysis found that the overall pooled PPV for sex chromosome aneuploidies was about 49%, with wide variation by condition. Turner syndrome had the lowest PPV at 32%, while XYY had the highest at about 71%.⁷ A single-center Korean study mirrored this pattern, finding an overall PPV of about 51% for sex chromosome aneuploidies, with Turner syndrome at just 19% and Triple X at 89%.⁸ Turner syndrome is particularly tricky because it frequently presents as mosaic in the placenta even when the fetus itself is unaffected, which inflates the false-positive rate.

Microdeletions and Rare Chromosomal Abnormalities

Some NIPT panels now offer screening for microdeletion syndromes, which involve small missing pieces of a chromosome rather than whole extra copies. This is the frontier where NIPT accuracy is weakest. In one cohort of about 8,100 pregnancies, only 36% of positive microdeletion or microduplication results were confirmed as true positives.⁹ A case report of a positive result for 22q11.2 deletion illustrates why: the deletion existed in the placenta but not in the baby, a scenario called confined placental mosaicism.¹⁰

There are efforts to improve these numbers. One recent study used a bioinformatics approach that distinguished whether the 22q11.2 deletion was coming from the maternal side or the fetal side of the cell-free DNA pool, achieving a PPV of 94% in cases that went on to amniocentesis.¹¹ But this kind of refined analysis is not yet standard across commercial labs.

Genome-wide NIPT can also flag rare autosomal trisomies like trisomy 16 or trisomy 22. A meta-analysis covering more than 740,000 screened pregnancies found that the true-positive rate for these rare findings varied widely depending on the specific chromosome involved.¹² These are situations where genetic counseling becomes especially important, because the clinical significance of many rare findings is uncertain.

Why Fetal Fraction Matters

The proportion of cell-free DNA in your blood that comes from the placenta, called the fetal fraction, directly affects how well NIPT works. If the fetal fraction is too low, the lab may not be able to distinguish a chromosomal difference from background noise. Most labs set a minimum threshold, commonly around 4%, below which they will not issue a result.

Fetal fraction increases as the pregnancy progresses but decreases with higher maternal body mass index and older maternal age.¹³ The relationship with BMI is particularly relevant. Research shows a clear inverse correlation between BMI and fetal fraction, and this is not because heavier women produce more total cell-free DNA. Total cell-free DNA concentration does not change with BMI; instead, women with higher BMI produce more of their own cell-free DNA, which dilutes the placental signal.¹⁴ This means that women with obesity are more likely to receive a “no result” from NIPT, particularly if blood is drawn early in pregnancy. Waiting a few weeks and redrawing can sometimes solve the problem, since the placenta grows and fetal fraction rises with gestational age.

When the Test Returns No Result

A “no result” or “test failure” is not the same as a negative result. It means the lab could not produce a reliable answer, often because fetal fraction was too low. This outcome deserves attention, not dismissal. Research suggests patients with NIPT failures face a meaningfully higher risk of rare fetal chromosomal abnormalities. One study found the odds of a rare chromosomal abnormality were nearly 19 times higher in pregnancies where NIPT failed compared to those with successful results.¹⁵

The same study found that NIPT failures were linked to higher rates of pregnancy complications including preeclampsia, gestational diabetes, fetal growth restriction, and preterm birth. These associations make biological sense: many of these complications involve abnormal placental function, and a poorly functioning placenta may shed less DNA into the maternal blood. Professional societies have recommended that women who receive a “no call” result be offered genetic counseling and invasive diagnostic testing rather than simply waiting and retesting.¹⁶

Biological Causes of False Positives

Because NIPT reads placental DNA rather than fetal DNA, any situation where the placenta’s chromosomes differ from the baby’s can produce a false positive. Confined placental mosaicism, where some cells in the placenta carry a chromosomal abnormality that the fetus does not, is the most common biological culprit.

A vanishing twin is another source of discordant results. In some twin pregnancies, one embryo stops developing early, but its placental tissue continues to release DNA fragments into the mother’s bloodstream for weeks after demise. If the lost twin was aneuploid, the NIPT can flag that aneuploidy even though the surviving baby is chromosomally typical.¹⁷ A systematic review of NIPT in pregnancies with a vanishing twin found that while the test could still detect common trisomies, the false positive rate was considerably higher than in singleton pregnancies.¹⁸ Some newer SNP-based NIPT platforms can detect additional fetal haplotypes, which helps identify vanishing twin situations and reduce the risk of false calls.¹⁹

Confirmation After a Positive Screen

Every major medical genetics society agrees: a positive NIPT result should be confirmed with invasive testing before any irreversible decision is made.²⁰ The two invasive options are chorionic villus sampling (CVS), which can be done earlier in pregnancy, and amniocentesis, performed slightly later. Both carry a small risk of miscarriage.

The choice between CVS and amniocentesis is not straightforward after NIPT. Some international societies recommend amniocentesis specifically because it samples fetal cells directly, avoiding the same confined placental mosaicism problem that can cause NIPT false positives in the first place.²¹ Others suggest that CVS is reasonable when ultrasound already shows abnormalities consistent with the NIPT finding, while amniocentesis is preferred when the ultrasound looks normal.²² In practice, the decision often comes down to timing, gestational age, and clinician experience.

How NIPT Compares to Older Screening

Before NIPT became widely available, first-trimester combined testing (FCT), which uses a combination of blood markers and ultrasound measurement of nuchal translucency, was the standard screening approach. FCT detects roughly 85-90% of Down syndrome cases with a false-positive rate of about 5%. NIPT substantially outperforms this on both counts.

A modeling study comparing different screening strategies found that genome-wide NIPT used as a first-tier screen yielded the highest number of diagnoses and required fewer invasive procedures per diagnosis than either targeted NIPT or first-trimester combined testing. Both NIPT approaches needed about 6 invasive tests per confirmed diagnosis, compared to 13 for FCT, meaning fewer women would undergo amniocentesis or CVS unnecessarily and fewer procedure-related miscarriages would occur.²³ The cost per diagnosed case was also lower with genome-wide NIPT.

Twin Pregnancies

NIPT works in twin pregnancies but comes with additional complexity. Meta-analyses have found it is still superior to serum and ultrasound-based screening for twins.²⁴ In dizygotic (non-identical) twins, the two placentas contribute different amounts of cell-free DNA, so labs need to ensure both fetal fractions meet the minimum threshold. If one twin has a much lower fetal fraction than the other, the test may miss an abnormality in that twin. Some platforms now estimate individual fetal fractions in dizygotic twin pregnancies to guard against this.²⁵

Screening for Single-Gene Conditions

NIPT originally focused on chromosomal aneuploidies, but the technology is expanding into screening for single-gene (monogenic) disorders like cystic fibrosis, sickle cell disease, and certain skeletal dysplasias. This version of the test, sometimes called sgNIPT, has been integrated into care for women already known to be at increased risk based on carrier status or family history.²⁶ Newer research platforms are exploring genome-wide fetal haplotyping that could simultaneously screen for aneuploidies and monogenic conditions from a single blood draw.²⁷

Whether sgNIPT should be offered to the general pregnant population, rather than only to those with known risk factors, remains debated. The technology is advancing faster than the counseling infrastructure needed to support it. Monogenic conditions are individually rare, which means PPV challenges similar to those seen with microdeletion screening will apply, and the interpretation of results will demand more specialized genetic counseling than most prenatal care settings currently provide.²⁸

Access and Insurance Barriers

Accuracy figures only matter if you can get the test in the first place. Access to NIPT varies significantly by socioeconomic status and insurance coverage. In one study, uptake of NIPT in socioeconomically disadvantaged neighborhoods was about 20%, compared to nearly 48% in other areas. Women in wealthier areas were more than three and a half times as likely to choose NIPT for prenatal screening.²⁹

Insurance coverage also creates paradoxes. In the United States, many private insurers still do not cover NIPT for women considered low-risk, even though the test outperforms the older screening it would replace. One study found that women with public insurance were actually more than three times as likely to have NIPT as their initial screen compared to women with private insurance, suggesting that private insurance restrictions are a real barrier.³⁰ When a test has demonstrably better performance and reduces the need for risky invasive procedures, the equity implications of restricting it based on insurance status are worth considering.

The Psychological Weight of a False Positive

A false positive on NIPT is not just a statistical curiosity. A systematic review of the psychological impact of false-positive results in prenatal screening found that these results produced an immediate spike in anxiety and distress for expectant parents, particularly mothers.³¹ The period between receiving a positive screen and getting a definitive result from amniocentesis can last weeks, during which parents face uncertainty about the health of their pregnancy. Some studies suggest residual anxiety can persist even after the false positive is resolved.

This is why the way results are communicated matters almost as much as the results themselves. When companies market NIPT as “99% accurate” without explaining the difference between sensitivity and positive predictive value, they set up a situation where a positive result feels like a near-certain diagnosis.³² A woman told her test is “over 99% accurate” and then told she screened positive for trisomy 13 might reasonably assume her baby almost certainly has the condition, when in reality the odds that her baby is actually affected may be closer to one in five. Pre-test counseling that explains what positive predictive value means in plain terms, and post-test counseling that contextualizes results before any decisions are made, can substantially reduce unnecessary anguish and prevent premature choices.